September 14, 2011
DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program
Posted by: admin : Category: Information
Lucentis receives Health Canada approval to treat vision loss from DMECohera’s TissuGlu Surgical Adhesive receives CE Mark approvalZimmer receives clearance for pediatric use of Universal Clamp Spinal Fixation SystemViamet commences VT-1161 Phase 1 clinical study to treat fungal infectionsFirst Edition: September 14, 2011Celecoxib inhibits GSK3 enzyme in lung cancer cells << Lucentis receives Health Canada approval to treat vision loss from DME
View the Original article
Related posts:
- Teen milk drinkers less likely to suffer from Type 2 diabetes
- UMA introduces new healthcare education and career resource center
- Novo Nordisk announces free diabetes educational e-book series
- Drug Companies Immunity for Swine Flu Vaccine; $2 Trillion Higher Deficit projected
Leave a Reply
You must be logged in to post a comment.
